The B-hCG curve in maternal serum in a normal pregnancy peaks at: A. 6 weeks of pregnancy. B. 8 weeks of pregnancy. C. 10 weeks of pregnancy. D. 14 weeks of pregnancy. E. 18 weeks of pregnancy.
| Source | Peak stated |
|---|---|
| Berek & Novak's Gynecology | ~10 weeks |
| Rosen's Emergency Medicine | 7–10 weeks, mean 50,000 IU/L |
| Henry's Clinical Diagnosis (Lab Methods) | ~10–12 weeks |
| Roberts & Hedges' Clinical Procedures | 10th–14th gestational weeks |
| Creasy & Resnik's Maternal-Fetal Medicine | 8–12 weeks, then declines |
Berek & Novak's Gynecology: "β-hCG levels peak at approximately 10 weeks…" Rosen's Emergency Medicine: "β-hCG levels should peak at the 7- to 10-week range."
QUE no 25: A 38-year-old G2P1 presents at 28 weeks of gestation with the history of headache and increase Blood Pressure of 160/100mmHg for 7 days but no history of body swelling. There is n detected in her urine. Which of following drug is MOST appropriate for this ACE inhibitors Beta blockers Methyl dopa diuretics
| Drug | Status in Pregnancy |
|---|---|
| Methyldopa | ✅ First-line — longest safety record, no fetal harm demonstrated |
| Beta-blockers (labetalol) | ✅ Used, but atenolol avoided; non-selective β-blockers may cause fetal bradycardia/IUGR |
| ACE inhibitors | ❌ Contraindicated — fetal renal dysplasia, oligohydramnios, pulmonary hypoplasia, fetal death |
| Diuretics | ❌ Not first-line — reduce already-decreased plasma volume in pregnancy; may worsen uteroplacental perfusion |
Brenner & Rector's The Kidney: "Methyldopa continues to be the first-line oral agent for the management [of hypertension in pregnancy]."
Creasy & Resnik's Maternal-Fetal Medicine: "Labetalol, nifedipine, and methyldopa are the recommended first-line agents for treatment of hypertension in pregnancy."
Harrison's Principles of Internal Medicine 22E: "ACE inhibitors and angiotensin-receptor blockers are contraindicated in pregnancy."
QUE no 20: A 40-years-old G2P1 at 17 weeks of gestation came for an antenatal checkup. She previously had Down syndrome baby and is concerned for this pregnancy. What is the ideal investigation for screening of Down syndrome in this patient? A. Combined screening test B. Quadruple test C.Serum BHCG D.Ultrasound for nuchal translucency
| Screening Test | Optimal Gestational Age | Components |
|---|---|---|
| Combined screening test | 11–13+6 weeks (1st trimester) | NT ultrasound + PAPP-A + β-hCG |
| Nuchal translucency (NT) alone | 11–13+6 weeks | Ultrasound only |
| Quadruple test | 15–20 weeks (2nd trimester) | AFP + uE3 + hCG + Inhibin A |
| Serum β-hCG alone | Not used as sole screening | Poor sensitivity alone |
Swanson's Family Medicine Review: "The quadruple test is currently used most widely in the United States for screening in the second trimester for Down syndrome. At a second-trimester cutoff of 1 in 250, the detection rate is 80%, with a 5% false-positive rate."
Emery's Elements of Medical Genetics and Genomics: "Low levels of uE3 and elevated levels of inhibin-A are associated with Down syndrome in the second trimester."